Promoting tissue regeneration through modulation of Wnt signalling
As part of our Monday seminar series, we are delighted to welcome our speaker:
Dr. Stephane Angers
Director, Donnelly Centre for Cellular & Biomolecular Research, University of Toronto
Hosted By
How to join
The event will be in person only, no need to register.
MSB 2170
Medical Sciences Building
University of Toronto
1 King’s College Circle
Toronto, ON M5S 1A8
Details are sent to the LMP community in the Friday events bulletin.
If you have any questions about this event, please contact Debb Yorke at lmp.chairadmin@utoronto.ca.
Speaker: Dr. Stephane Angers
Dr. Angers is an expert in the field of signal transduction. He obtained his Ph.D from the Université de Montréal in 2002 under the guidance of Dr. Michel Bouvier. His thesis work led to the development and application of light energy transfer methodology for the study of protein-protein interaction and signal transduction. From 2002-2006 he was a Howard Hughes Post-Doctoral Fellow at the University of Washington in Seattle under the supervision of Dr. Randall T. Moon, where he identified and characterized novel components of the Wnt signalling pathway and the Cul4 family of E3 ubiquitin ligases that enabled the PROTAC drugs.
In October 2006, Dr. Angers established his independent research program in the Department of Pharmaceutical Sciences at the Faculty of Pharmacy and in the Department of Biochemistry at the University of Toronto. In September 2021, Dr. Angers was named Director of the Donnelly Centre of Cellular and Biomolecular Research at the University of Toronto, an internationally recognized Research Institute bringing together multidisciplinary teams of scientists. His research program is developed to understand the signalling mechanisms underlying the Wnt and Hedgehog families of growth factors and their signalling mechanisms in development, adult tissue homeostasis and in human diseases. His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway for the treatment of cancers and regenerative medicine applications. He is the scientific founder of two biotech companies, ModMab Therapeutics and AntlerA Therapeutics, which are pursuing the clinical development of these molecules.
